MCET News 08/25/2014 19:22:37 $MCET Agreed, tob999. Simply

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
MCET News 08/25/2014 19:22:37 $MCET
Agreed, tob999. Simply stated, the technology that MultiCell has developed would not only effectively target cancer cells, but also provide the patient with some sort of preventive shield against the formation of new tumors.

Quote:
This is a major league patent if these results can be replicated in humans:


Quote:
In mouse cancer models, the combination of MCT-465, a dsRNA therapeutic, and MCT-475, an IgP therapeutic, not only induced the animal's immune system to eradicate the engrafted tumor, but upon rechallenge with tumor cells, no new tumors developed indicating the animal had developed protective anti-tumoral immunity


MCET
This is a major league patent if these results can be replicated in humans:

Quote:
In mouse cancer models, the combination of MCT-465, a dsRNA therapeutic, and MCT-475, an IgP therapeutic, not only induced the animal's immune system to eradicate the engrafted tumor, but upon rechallenge with tumor cells, no new tumors developed indicating the animal had developed protective anti-tumoral immunity


MCET Stock Message Board http://investorshangout.com/Multicell-Techs-Inc-MCET-64069/

MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer


Aug 25, 2014 7:51 AM CT


MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer PR Newswire WOONSOCKET, R.I., Aug. 25, 2014 WOONSOCKET, R.I., Aug. 25, 2014 /PRNewswire/ --MultiCell Technologies, Inc. (OTC: MCET) has been issued U.S. patent 8,809,290 covering novel drug compositions and platform technologies which redirect the immune system response to protect against highly virulent virus infection and cancer. These novel drug compositions consisting of noncoding doubled stranded RNA (dsRNA) molecules and recombinant immunoglobulin-peptide (IgP) molecules demonstrate unique immune stimulating activity, and the ability to present peptide antigens to immune cells resulting in protective anti-tumoral and anti-viral immunity. In mouse cancer models, the combination of MCT-465, a dsRNA therapeutic, and MCT-475, an IgP therapeutic, not only induced the animal's immune system to eradicate the engrafted tumor, but upon rechallenge with tumor cells, no new tumors developed indicating the animal had developed protective anti-tumoral immunity. Tumor rejection and protection against similar and new tumor variants was found to also be associated with specific, overall expansion of cytokine producing cells. This finding indicates a broadening of the repertoire of anti-tumor immune cells and the development of immune memory in the animal. Mice immunized with MCT-465 and MCT-475 resulted in the priming of an immune response capable of limiting the replication of virus subsequent to further virus infectious challenge. During viral infection, specific immune system cells begin to proliferate and differentiate which defines the adaptive immune response to the infection. In mouse models, administration of MCT-465 and MCT-475 greatly enhanced the generation of interferon gamma (IFN?) and interleukin-2 (IL-2) producing virus antigen-specific T-cells resulting in significantly reduced virus levels present in the animal. MultiCell is developing MCT-465 and MCT-475 for the treatment of hepatitis B virus infection and hepatitis C virus infection, and for the treatment of certain cancers. Chronic hepatitis B and chronic hepatitis C virus infection are recognized as major factors worldwide that increase the risk of hepatocellular carcinoma. According to the U.S. National Cancer Institute (NCI), chronic hepatitis B virus infection and chronic hepatitis C virus infection account for about 30% to 40% of all reported USA cases of hepatocellular carcinoma. Treatment of hepatocellular carcinoma, the most common form of primary liver cancer, represents a major unmet medical need. Hepatocellular carcinoma is a leading cause of cancer death worldwide, and is the fourth most common cancer in the world. Over 1 million cases of hepatocellular carcinoma are reported annually worldwide. Current approaches for treatment of hepatocellular carcinoma are of limited efficacy. According to the NCI, only 16% of patients diagnosed with primary liver cancer survive longer than 5 years. MultiCell is also developing MCT-485, a very small dsRNA therapeutic, thought to target cancer by delivering a cytotoxic effect to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells. MCT-485 appears to have no effect on cells not directly involved in the process of relapse, progression and metastasis of cancer. MCT-485 appears to exert a preferential biological activity on liver cancer cells while showing no effect on normal liver cells. About MultiCell Technologies, Inc. MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools for the treatment of primary multiple sclerosis-related fatigue and cancer
agreed 100%...a patent for CANCER....multi days RNNER...also imho....
Patent Assignment Abstract of Title

NOTE:Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staf
Total Assignments: 1


Patent #:


8809290


Issue Dt:


08/19/2014


Application #:


13078119


Filing Dt:


04/01/2011




Publication #:


20110274705


Pub Dt:


11/10/20
Inventors:


Adrian Bot, Lilin Wang, Dan Joseph Smith, Luis A. Dellamary et al




Title:


METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF T CELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS

Assignment:
Reel/Frame:

032095/0584


Recorded: 01/30/2014


Pages: 7


Conveyance:

ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).


Assignors:
WANG, LILIN

Exec Dt:


08/13/2012

DELLAMARY, LUIS A.

Exec Dt:


08/16/2012

PHILLIPS, WILLIAM JOSEPH, JR.

Exec Dt:


08/16/2012

SMITH, DAN JOSEPH

Exec Dt:


08/16/2012

BOT, ADRIAN

Exec Dt:


08/22/2012

Assignee:

MULTICELL IMMUNOTHERAPEUTICS, INC.



68 CUMBERLAND STREET



SUITE 301



WOONSOCKET, RHODE ISLAND 02895








Correspondent:





KEVIN M. FARRELL



100 SUMMER STREET



SUITE 2250



BOSTON, MA 02110



You're welcome. The interesting thing is that in most industries, a company would need to have significant revenues, or a well known brand name, to be of any value to a potential suitor.

But in the pharmaceutical business, it is a whole different ball game. The right research & development combined with the right patent(s) can result in a huge buyout offer from one of the big players. Sometimes they'll make a huge offer just to keep one of their major competitors from getting the patent(s).

I think we might see some excitement here in the coming days.

A always, simply my opinion.

Quote:
thx!..very educational...WOW!


MCET
Imagine a buyout offer .. Penny land
thx!..very educational...WOW!
Recently Merck tendered an offer of more than $3 billion to acquire Idenix Pharmaceuticals Inc . Idenix is a 'biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases'.

According to their 10-K filing, Idenix only had revenue of $469,000 for all of CY 2013 (see link below for filing), no revenue for Q1 or Q2 of 2014 (according to google finance), and has been bleeding money for several years.

Yet Merck has tendered an offer valued at more than $3 billion, because of the patents they own and the research they have conducted.

So here's an intriguing piece of info... Merck only derived about 3% of its revenue in Q1 2013 from Cancer related drugs. When an industry giant is weak in a particular area, they often use acquisitions to strengthen their weakest areas.

It would seem plausible that a company like Merck, who has already demonstrated their willingness and desire to acquire smaller companies, might eventually be willing to buy a company like MultiCell (for their research performed and patents held). And based upon the $3 billion Merck will be paying for Idenix (with little or no recent revenue), any possible offer could be rich indeed. Could you imagine how an OTC stock would react if Merck expressed some interest in owning them?

As always, simply my opinion.

Merck Completes Tender Offer to Acquire Idenix
http://www.marketwatch.com/story/merck-comple...2014-08-05

Why Did Merck Pay Such A Huge Premium For Idenix?
http://www.forbes.com/sites/greatspeculations...or-idenix/


Link to Idenix Pharmaceuticals Inc 2013 10-K:
http://www.sec.gov/Archives/edgar/data/109364...-index.htm

MCET

Tomorrow another 50% up
ok, the same to u!
lol!
Actually, it is not directly assigned to MCET, I'd take a look.
Missed Simple Simon today. We can now say his bashing ammunition has been narrowed by at least 2 things.

1. MCET does absolutely nothing
2. No patents in MCET's name. (This one is)
Looks like shorting happened on MCET. Short covering tomorrow
* * $MCET Video Chart 8-25-14 * *

Link to Video - click here to watch the technical chart video
realistically this attempts to go touch .0020 - .0022 the high from the last run, will likely fail there....


700m vol says this is more then one day play.


Eow high.....guesses? Nice base here
IP (intellectual property) on the production of wine by the glass was offered up for an investment on Shark Tank, and I recall one of the sharks offering several million dollars (with an intent to license out the patent rights).

So how much might one of the big pharma boys (such as Merck, Pfizer, etc) be willing to pay for the patent(s) which not only effectively target cancer cells, but also provide the patient with some sort of preventive shield against the formation of new tumors? I would think the starting price would have to be at least in the tens of millions of dollars, if not more.

Here's an exerpt from today's PR:
'In mouse cancer models, the combination of MCT-465, a dsRNA therapeutic, and MCT-475, an IgP therapeutic, not only induced the animal's immune system to eradicate the engrafted tumor, but upon rechallenge with tumor cells, no new tumors developed indicating the animal had developed protective anti-tumoral immunity. Tumor rejection and protection against similar and new tumor variants was found to also be associated with specific, overall expansion of cytokine producing cells. This finding indicates a broadening of the repertoire of anti-tumor immune cells and the development of immune memory in the animal'

As always, simply my opinion.

MCET
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PenFed’s Toys for Tots Drive Targets Holiday Gift Gaps

Updated Category News Views 94

A missing present under a tree is not a statistic anybody ought to glide past. PenFed Credit Union has opened its annual Toys for Tots collection across Washington-region branches, taking new, unwrapped toys through December 8 at 1:00 p.m. ET. The useful detail, and frankly the one worth remembering when people default to buying the easiest shiny thing on a shelf, is...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 13

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
Humana's Medicare Audit Shock Puts Disclosure in Focus

Updated Category News Views 156

Medicare Advantage just reminded Wall Street that reimbursement plumbing can wreck a perfectly calm-looking stock in a hurry. Humana shareholders watched that lesson land hard on November 18, when reports surfaced of a proposed federal CRUSH rule aimed at fraud, waste, and improper payments in the program. The reported response in NYSE:HUM was ugly: an early account put...

Continue Reading
Africa’s Digital Leap Still Has a 64% Usage Problem

Updated Category News Views 111

A continent can be blanketed in signal and still feel digitally stranded. That is the stubborn fact sitting inside the GSMA Digital Africa Index 2026: mobile broadband reaches 92% of Africa’s population, while only 28% use mobile internet on their own devices. The 64% usage gap is not a rounding error or a tidy policy footnote. It is the whole unfinished job. From an...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 193

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 69

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 104

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 101

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
ACOLT Bets on Gold, Craft, and a Sci-Fi Story World

Updated Category News Views 205

A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading

Top 5 Most Recently Viewed Articles

Important Update for Centene Investors on Class Action Case

Updated Category News Views 125

Overview of the Class Action Lawsuit Against Centene A critical reminder has emerged for investors of Centene Corporation regarding the ongoing class action lawsuit. The litigation is focused on allegations that may involve significant losses for shareholders, particularly those whose financial stakes in the company have been adversely affected. Lead Plaintiff Deadline...

Continue Reading
Keith Gabel and Sercomm to Unveil Innovations at SCTE TechExpo

Updated Category News Views 299

Keith Gabel to Join Sercomm at SCTE TechExpo for Product Launch Sercomm, a renowned provider in the telecom and broadband sector, is set to make waves at the upcoming SCTE TechExpo. The company is excited to announce that U.S. Paralympic and World Champion snowboarder, Keith Gabel, will be a special guest during this significant event. This collaboration spotlights not...

Continue Reading
Crafting a Small Biz Site That Converts Consistently

Updated Category News Views 28

Making an Impression: Small Biz Website Must-Haves First impressions aren't just for dinner parties or nervous job interviews. They're the bread and butter of small business websites, and if you flub it, your visitors are gone before you can blink. Sean O'Kelly, a digital marketing whiz, throws down some knowledge in HelloNation, drilling into what makes a small business...

Continue Reading
Cooper Standard Launches Innovative FlexiCore Thermoplastic Seal

Updated Category News Views 88

Revolutionizing Automotive Sealing Solutions Cooper Standard, a premier global supplier in sealing and fluid handling, is once again leading the industry with the introduction of the FlexiCore™ Thermoplastic Body Seal. This innovative product represents a significant leap in automotive sealing technology, aiming to provide a more sustainable, lightweight, and efficient...

Continue Reading
Coupang Securities Class Action: Investors' Rights Explained

Updated Category News Views 166

Coupang Securities Class Action Overview In the world of investments, staying informed is crucial, especially when facing legal challenges. The case involving Coupang, Inc. has drawn significant attention recently, primarily due to allegations of securities fraud linked to a data breach and subsequent stock decline. This case emphasizes the importance of understanding how...

Continue Reading